Urogen Pharma $URGN Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. decreased its stake in Urogen Pharma (NASDAQ:URGN) by 1.3% during the third quarter, Holdings Channel reports. The institutional investor owned 2,199,652 shares of the company’s stock after selling 30,000 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Urogen Pharma were worth $43,883,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Walleye Capital LLC acquired a new position in Urogen Pharma in the second quarter valued at approximately $4,742,000. Squarepoint Ops LLC boosted its position in Urogen Pharma by 187.8% in the 2nd quarter. Squarepoint Ops LLC now owns 94,309 shares of the company’s stock worth $1,292,000 after purchasing an additional 61,545 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Urogen Pharma during the 3rd quarter worth approximately $977,000. Privium Fund Management B.V. grew its stake in shares of Urogen Pharma by 82.7% during the 3rd quarter. Privium Fund Management B.V. now owns 196,622 shares of the company’s stock worth $3,923,000 after purchasing an additional 89,000 shares during the period. Finally, NEOS Investment Management LLC purchased a new position in shares of Urogen Pharma during the 3rd quarter valued at approximately $1,007,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Urogen Pharma

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,479 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $147,261.51. Following the transaction, the general counsel directly owned 51,326 shares of the company’s stock, valued at $1,010,608.94. This trade represents a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mark Schoenberg sold 7,373 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $145,174.37. Following the transaction, the insider directly owned 144,985 shares in the company, valued at approximately $2,854,754.65. The trade was a 4.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 4.70% of the stock is currently owned by insiders.

Urogen Pharma Trading Up 4.3%

Shares of URGN opened at $20.46 on Monday. The firm has a market cap of $995.99 million, a P/E ratio of -6.39 and a beta of 1.34. Urogen Pharma has a 12 month low of $3.42 and a 12 month high of $30.00. The stock’s 50 day moving average is $20.89 and its two-hundred day moving average is $20.89.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Monday, March 2nd. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.12. The business had revenue of $37.84 million for the quarter, compared to analyst estimates of $39.92 million. Equities research analysts forecast that Urogen Pharma will post -3.12 EPS for the current year.

Key Urogen Pharma News

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: Earnings beat improves near-term sentiment — UroGen reported Q4 results on March 2 that topped EPS expectations (reported loss narrower than consensus) which likely helped lift the stock as investors re-price near-term performance and execution. Urogen Pharma Shares Gap Up After Earnings Beat
• Positive Sentiment: Pipeline / financing optionality could drive upside — coverage notes that management is weighing ENVISION program success and the possibility of an expanded loan to fund the bladder cancer push; progress on ENVISION or secured financing would reduce execution risk and support commercialization/late‑stage activity. UroGen Weighs ENVISION Success And Expanded Loan In Bladder Cancer Push
• Neutral Sentiment: Inducement equity grants announced — the company disclosed inducement grants under Nasdaq Rule 5635(c)(4), a routine step to attract or retain executives; useful for talent but potentially dilutive depending on size and vesting. UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Negative Sentiment: Analyst cuts to 2026 guidance increase downside risk — HC Wainwright materially lowered FY2026 EPS forecasts (now deeper losses) and trimmed Q2–Q4 estimates, signaling weaker near-term profitability expectations; while the firm lifted its FY2027 view to a positive EPS, the nearer-term cuts can pressure sentiment and valuation until clinical/financial catalysts are clearer. HC Wainwright lowed 2026 EPS estimates for Urogen Pharma

Analyst Ratings Changes

Several research firms recently issued reports on URGN. Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a research note on Monday, March 2nd. D. Boral Capital reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Urogen Pharma in a report on Monday, March 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.29.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.